Regeneron Q2: Beat & Battle
Hello! Today, I've brought this topic to you! We're diving into the latest earnings report from the biotech giant Regeneron (NASDAQ: REGN), and it's a fascinating story of huge successes mixed with significant challenges. The company just posted quarterly results that blew past Wall Street's expectations, but a closer look reveals a more complex picture. Let's break down what you need to know! ☆ Topic 1: A Massive Earnings Beat The biggest headline from Regeneron's Q2 2025 report was its incredible profitability. The company reported a Non-GAAP earnings per share (EPS) of $12.89 . To put that in perspective, market analysts were only expecting an EPS of $8.43. That's a stunning 53% beat! Imagine you're running a coffee shop, and experts predict you'll make an $8 profit for the day. At closing time, you count the cash register and discover you've actually made nearly $13. That’s the kind of positive surprise Regeneron delivered. Revenue...